Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00063323 · ClinicalTrials.gov registry record · Phase 3
Maintenance Treatment for Abstinent Smokers
A Phase 3 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 3
- Development phase
- 589
- Enrollment target
NCT00063323 is a Phase 3 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 589 participants.
The verdict
NCT00063323, a Phase 3 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 589 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy and cost-effectiveness of long-term pharmacotherapy (using Zyban and/or nicotine replacement) for reducing the relapse rate associated with stopping smoking.
Interventions
- DRUG Bupropion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 589 participants |
| Start Date | 2000-08 |
| Est. Completion | 2006-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00063323
The ClinicalTrials.gov registry entry for NCT00063323 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 589 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bupropion is the first listed.
NCT00063323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00063323 about?
NCT00063323 is a clinical study titled "Maintenance Treatment for Abstinent Smokers". The purpose of this study is to determine the efficacy and cost-effectiveness of long-term pharmacotherapy (using Zyban and/or nicotine replacement) for reducing the relapse rate associated with stopping smoking.
What is the current status of trial NCT00063323?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 589 participants. The study started on 2000-08. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00063323?
The interventions under investigation include: Bupropion (DRUG).
Who is sponsoring clinical trial NCT00063323?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.